More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular ...

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Brolucizumab ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion. This is the third ...